237 related articles for article (PubMed ID: 21777622)
1. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2.
Zhang Q; Liu Z; Mi Z; Li X; Jia P; Zhou J; Yin X; You X; Yu L; Guo F; Ma J; Liang C; Cen S
Antiviral Res; 2011 Sep; 91(3):321-9. PubMed ID: 21777622
[TBL] [Abstract][Full Text] [Related]
2. High-Throughput NanoBiT-Based Screening for Inhibitors of HIV-1 Vpu and Host BST-2 Protein Interaction.
Li B; Dong X; Zhang W; Chen T; Yu B; Zhao W; Yang Y; Wang X; Hu Q; Wang X
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502213
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of a high-throughput screening assay for interaction inhibitor between BST-2 and Vpu].
Pang XJ; Hu SQ; Zhang Y; Cen S; Jin Q; Guo F
Bing Du Xue Bao; 2012 Nov; 28(6):633-8. PubMed ID: 23367562
[TBL] [Abstract][Full Text] [Related]
4. A novel peptide to disrupt the interaction of BST-2 and Vpu.
Mi Z; Wang X; He Y; Li X; Ding J; Liu H; Zhou J; Cen S
Biopolymers; 2014 May; 102(3):280-7. PubMed ID: 24676648
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
Fritz JV; Tibroni N; Keppler OT; Fackler OT
Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
[TBL] [Abstract][Full Text] [Related]
6. A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.
Mi Z; Ding J; Zhang Q; Zhao J; Ma L; Yu H; Liu Z; Shan G; Li X; Zhou J; Wei T; Zhang L; Guo F; Liang C; Cen S
Sci Rep; 2015 Dec; 5():18499. PubMed ID: 26669976
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the interface of the bone marrow stromal cell antigen 2-Vpu protein complex via computational chemistry.
Zhou J; Zhang Z; Mi Z; Wang X; Zhang Q; Li X; Liang C; Cen S
Biochemistry; 2012 Feb; 51(6):1288-96. PubMed ID: 22264038
[TBL] [Abstract][Full Text] [Related]
8. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.
Bolduan S; Votteler J; Lodermeyer V; Greiner T; Koppensteiner H; Schindler M; Thiel G; Schubert U
Virology; 2011 Jul; 416(1-2):75-85. PubMed ID: 21601230
[TBL] [Abstract][Full Text] [Related]
9. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
Neil SJ; Zang T; Bieniasz PD
Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
[TBL] [Abstract][Full Text] [Related]
10. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
11. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
12. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
13. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
14. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
16. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
17. Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients.
Vanwalscappel B; Rato S; Perez-Olmeda M; Díez Fuertes F; Casartelli N; Alcami J; Mammano F
Virology; 2017 Jan; 500():247-258. PubMed ID: 27855354
[TBL] [Abstract][Full Text] [Related]
18. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
19. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
20. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
